Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035815 · ClinicalTrials.gov registry record · Phase 3
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00035815: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT00035815 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 330 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035815, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.
Interventions
- DRUG Placebo
- DRUG Insulin like growth factor, type 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035815
The ClinicalTrials.gov registry entry for NCT00035815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00035815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035815 about?
NCT00035815 is a clinical study titled "Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial". The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinati...
What is the current status of trial NCT00035815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2003-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00035815?
The interventions under investigation include: Placebo (DRUG), Insulin like growth factor, type 1 (DRUG).
Who is sponsoring clinical trial NCT00035815?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.